Abstracts tagged "Comorbidity"

Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Dominique Feterman Jimenez¹, Rachael Stovall¹, Jose Andres Porres Arnaez², Vishwesh Bharadiya³, Jean Liew⁴, Alison Bays¹, Thomason Jenna⁵, Londyn Robinson⁶, Rashmi Dhital⁷ and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Universidad Francisco Marroquin, Guatemala, ³AIIMS, New Delhi, India, ⁴Boston University, Boston, MA, ⁵University of Washington, Division of Rheumatology, Seattle, WA, ⁶University of Washington, Durham, NC, ⁷UC San Diego, Brentwood, TN, ⁸University of Washington, Bellevue, WA
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
Abstract Number: 0310 • ACR Convergence 2024
I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR)…
Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 0409 • ACR Convergence 2024
Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis
Irene Chern¹, Jade Singleton², Xing Wang³ and Jordan Jones⁴, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Seattle Children's Hospital, Seattle, ³Biostatistics Epidemiology and Analytics in Research, Seattle Children’s Research Institute, Seattle, WA, ⁴Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Down syndrome (DS), a disorder caused by triplication of chromosome 21, affects around 1 in 1000 births making it one of the most common…
Abstract Number: 1336 • ACR Convergence 2024
Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³ and Masayoshi Harigai⁴, ¹Meiji Pharmaceutical University, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ³Showa University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, there are concerns about the risk of malignancy…
Abstract Number: 2467 • ACR Convergence 2024
Elderly Systemic Sclerosis. Clinical Presentation and Outcome
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³, Ismael Gonzalez⁴, Ignacio Gonzalez Fernandez⁵, Carolina Díez Morrondo⁵, Carolina Alvarez Castro⁶, Paula Perez Garcia⁵, Jose Ordas Martínez⁵, Pedro Baenas Gonzalez⁵ and elvira Diez álvarez⁵, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, León, Spain, ⁵Complejo Asistencial Universitario de Leon, Leon, ⁶Complejo Asistencial Universitario de Leon, Leon, Spain
Background/Purpose: Immunosenescence refers to the gradual deterioration of the immune system associated with aging, leading to an increased incidence of infections, cancer, and autoimmune diseases.…
Abstract Number: 0985 • ACR Convergence 2023
Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry
Daniel Solomon¹, Fredrik Johansson², Hongshu Guan³, Leah Santacroce⁴, Lin Guo⁵, Wendi Malley⁵ and Heather Litman⁵, ¹Brigham and Women's Hospital, Newton, MA, ²Chalmers University of Technology, Goteborg, Sweden, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵CorEvitas, LLC, Waltham, MA
Background/Purpose: Comorbid conditions are very common in rheumatoid arthritis (RA) and several prior studies have derived comorbidity clusters using machine learning (ML). Clustering using ML…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 1078 • ACR Convergence 2023
Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression
Yashswee KC¹ and Rochella Ostrowski², ¹Loyola University, Oakpark, IL, ²Loyola University Medical Center, Maywood, IL
Background/Purpose: Coronavirus disease 2019 (COVID-19) can have varying outcomes. Patients with chronic conditions or immunosuppression experience more severe illness. Both organ transplant recipients and patients…
Abstract Number: 1966 • ACR Convergence 2023
Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?
Federico Fattorini¹, Chiara Cardelli¹, Simone Barsotti², Michele Diomedi¹, Elenia Laurino¹, Mariano Grosso³, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy
Background/Purpose: Anti-synthetase syndrome (ASS) is an idiopathic inflammatory myopathy, typically characterized from the triad interstitial lung disease (ILD), myositis and arthritis, together with anti-aminoacyl tRNA…
Abstract Number: 1212 • ACR Convergence 2023
Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus
OKEOGHENE AKPOIGBE¹, YONG EUN², COMFORT ANIM-KORANTENG² and AMANDA SAMMUT², ¹NYCHH- HARLEM, Bronx, NY, ²NYCHH- HARLEM, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic multisystemic immune-mediated disease with often nonspecific symptoms, associated with recurrent flares that can be life threatening. Prevalence…
Abstract Number: 1969 • ACR Convergence 2023
Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study
Marco Fornaro¹, Vincenzo Venerito², Florenzo Iannone³, Naveen R⁴, Elena Nikiphorou⁵, Mrudula Joshi⁶, Ai Lyn Tan⁷, Sreoshy Saha⁸, Samuel Shinjo⁹, Vishwesh Agarwal¹⁰, Nelly Ziade¹¹, Tsvetelina Velikova¹², Esha Kadam¹³, Marcin Milchert¹⁴, Ioannis Parodis¹⁵, Abraham Edgar Gracia-Ramos¹⁶, Lorenzo Cavagna¹⁷, Masataka Kuwana¹⁸, Johannes Knitza¹⁹, Ashima Makol²⁰, Dey Dzifa²¹, CARLOS ENRIQUE TORO GUTIERREZ²², CARLO VINICIO CABALLERO²³, Oliver Distler²⁴, Jessica Day²⁵, Hector Chinoy²⁶, Vikas Agarwal⁴, Rohit Aggarwal²⁷, Latika Gupta²⁸ and COVAD Study Group²⁹, ¹University of Bari, Grottaglie, Italy, ²Rheumatology Department, Università degli Studi di Bari, Bari, Italy, ³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ⁵King's College London, London, United Kingdom, ⁶Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune, India, ⁷University of Leeds, Leeds, United Kingdom, ⁸Mymensingh Medical College, Faridpur, Bangladesh, ⁹Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil, ¹⁰Mahatma Gandhi Missions Medical College, Lucknow, India, ¹¹Saint-Joseph University, Beirut, Lebanon, ¹²Department of Clinical Immunology, Medical Faculty, University Hospital "Lozenetz", Sofia University St. Kliment Ohridski, Sofia, Bulgaria, ¹³Seth Gordhandhas Sunderdas Medical College and King Edwards Memorial Hospital, Mumbai, India, ¹⁴Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹⁵Karolinska Institutet, Stockholm, Sweden, ¹⁶Department of Internal Medicine, General Hospital, National Medical Center "La Raza", Instituto Mexicano del Seguro Social, Av. Jacaranda S/N, Col. La Raza, Del. Azcapotzalco, C.P. 02990, Mexico City, Mexico, ¹⁷Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, ¹⁸Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ¹⁹Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ²⁰Mayo Clinic, Rochester, MN, Rochester, MN, ²¹Department of Medicine and Therapeutics, University of Ghana School of Medicine and Dentistry, College of Health Sciences, Korle-Bu, Accra, Ghana, ²²Centro de Estudios de Reumatología y Dermatología SAS, Cali, Colombia, ²³REUMACARIBE IPS, Barranquilla, Colombia, ²⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²⁵Walter and Eliza Hall Institute, Melbourne, Australia, ²⁶The University of Manchester, Sale, United Kingdom, ²⁷University of Pittsburgh, Pittsburgh, PA, ²⁸Royal Wolverhampton Trust, Wolverhampton/University of Manchester, United Kingdom, ²⁹-, -
Background/Purpose: Comorbidities have a profound impact on the quality of life (QoL), though global data on the burden of comorbidities and its impact on health…
Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
Abstract Number: 2029 • ACR Convergence 2023
Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?
Chiara Cardelli¹, Simone Barsotti², Elenia Laurino¹, Michele Diomedi¹, Federico Fattorini¹, Dina Zucchi³, Alessandra Tripoli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy, ³Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy; Department of Medical Biotechnologies, University of Siena, Pisa, Italy
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) are rare, multisystemic and complex diseases that strongly impact the Quality of Life (QoL) of those affected. Patient Reported Outcomes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.